A single-blind human clinical trial on Saanroo’s Trpti finds that the ingredient supports nutrient sensing and the body’s natural incretin response. The company says this strengthens the scientific body of evidence behind its bioavailable oleoylethanolamide (OEA) for metabolic health and weight management. The human clinical study found that, compared with placebo, one dose of 300 mg of Trpti significantly increased post-meal GLP-1 and gastric inhibitory polypeptide (GIP) responses in healthy adults in the overweight to obese body mass index (BMI) range. Saanroo notes that this effect was observed within 15 minutes of ingestion, and recurred after subsequent meals.